THE JOHNS HOPKINS UNIVERSITY and Bristol-Myers Squibb Co. announced a five-year collaboration aimed to answer why some patients respond to checkpoint blockers and some do not, and to develop more effective combination immunotherapies. Projects included in the collaboration will span laboratory research on patients’ tumor samples and several early-stage clinical trials led by Johns Hopkins...
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
